Supernus Pharmaceuticals seeks FDA approval for ADHD drug

The fate of a local company’s treatment for attention deficit hyperactivity disorder is now in regulators’ hands.

Supernus Pharmaceuticals Inc. (NASDAQ: SUPN) has submitted its application to the Food and Drug Administration to take its ADHD drug to market, the company announced Monday. If granted, that could mean getting the treatment to patients in the second half of 2020.